New York, USA – September 30, 2022 – RNA-Solutions is a platform for revolutionary research in RNA, targeting coding and non-coding RNAs with different physiological functions. Scientists at CD Genomics are ready to help detect various types of RNAs via meticulous and integrative approaches. Powered by the Illumina, Pacbio SMRT, and Nanopore sequencing platforms, CD Genomics offers services performed by de novo and reference-based transcriptome analysis of the global transcriptome response.

RNA is a single-stranded nucleic acid complementary to the DNA strand formed during transcription. Meanwhile, mRNA determines the amino acid sequence of proteins and completes the process of transferring genetic information from RNA to protein. Although non-coding RNAs such as miRNA, lncRNA and circRNA cannot be translated into proteins, they are functional RNA molecules that regulate gene expression through post-transcriptional or transcriptional levels. The analysis of coding mRNAs and non-coding RNAs is important to reveal the molecular mechanisms of post-transcriptional regulation.

The whole transcriptome is the sum of all transcripts, including mRNA and non-coding RNA (ncRNA), that can be transcribed by a particular species, tissue or cell type under a certain period or condition of treatment. The whole transcriptome sequencing, as it is currently called, mainly detects mRNA and three types of ncRNAs, that is, lncRNA, circRNA and miRNA. Whole transcriptome sequencing allows the analysis of the interactions and co-expression regulatory networks between various RNAs, as well as competing endogenous RNAs (ceRNAs).

In addition to exploring competing ceRNA networks, whole transcriptome sequencing has a wide range of applications in clinical research and clinical diagnostics, from standard gene expression analysis to advanced analysis such as pathway and alternative splicing analysis, cell type revelation and heterogeneity, classification of tissue types and diseases, and biomarker prediction.

“Our Whole Transcriptome Sequencing Services are based on the Illumina, Pacbio SMRT and Nanopore high-throughput sequencing platforms and are capable of detecting the overall transcript level of any species at the single nucleotide level,” commented the Vice President of CD Genomics.

“Based on next-generation sequencing, whole-transcriptome sequencing offers a wide range of applications, from mRNA analysis to analysis of the entire transcriptome, including mRNA and non-coding RNA,” he further added. “Our whole transcriptome sequencing enables the characterization of competing for endogenous RNA (ceRNA) networks to explore complex post-transcriptional regulatory mechanisms. The structure and expression characteristics can be analyzed along with the discovery of unknown and rare transcripts, and the accurate identification of variable shear sites and coding sequence single nucleotide polymorphisms (cSNPs), providing the most comprehensive information on the transcriptome.”

About CD Genomics

CD Genomics enjoys a high reputation for sequencing, microarray analysis, library construction and genotyping, providing reliable services to pharmaceutical and biotechnology companies, academia, and government agencies.

Media Contact
Company Name: CD Genomics
Contact Person: Kiko Garcia
Email: Send Email
Phone: 1-631-259-7705
Country: United States
Website: https://www.cd-genomics.com